CRP and rheumatoid arthritis: Using CRP levels as a surrogate for inflammation, baricitinib plus methotrexate was associated with greater relief from the non-inflammatory component of RA-associated pain than adalimumab plus methotrexate or placebo plus methotrexate [28].